

**Session Title:** #169: Highlights of the Day III

**Session Type:** Highlights of the Day

**Date:** Tuesday, June 8

**Location:** E Hall D1

**Time:** 7:30 AM - 9:00 AM

- Highlights of the Day III  
*Kathy Miller, MD*
  - Discussion: Breast Cancer - Local/Regional and Adjuvant Therapy  
*Kathy Miller, MD*
  - Discussion: Lung Cancer - Metastatic  
*Charles M. Rudin, MD, PhD*
  - Discussion: Sarcoma  
*Gary K. Schwartz, MD*
  - Discussion: Gastrointestinal (Noncolorectal) Cancer  
*C. D. Blanke, MD*
  - Discussion: Head and Neck Cancer  
*Everett E. Vokes, MD*
- 

**Session Title:** #18: Building Bridges for Successful Breast Cancer Survivorship Care

**Session Type:** Education Session

**Date:** Tuesday, June 8

**Location:** E354a

**Time:** 8:00 AM - 9:15 AM

- Coordination of Care in Breast Cancer Survivors: An Overview  
*Claire Frances Snyder, PhD*
- Impact of Comorbid Conditions on Breast Cancer Survivorship  
*Sharon Hermes Giordano, MD*
- Information and Training Needs of Primary Care Providers to Promote Quality Care for Breast Cancer Survivors  
*Larissa Nekhlyudov, MD, MPH*

- Communication Strategies, Models, and Tools for Partnerships between Primary Care and Oncology Care to Provide Quality Breast Cancer Survivorship Care

*Eva Grunfeld, MD, D.Phil.*

---

**Session Title:** #27: Comparative Effectiveness Research in Oncology: Opportunities and Challenges

**Session Type:** Education Session

**Date:** Tuesday, June 8

**Location:** S404

**Time:** 8:00 AM - 9:15 AM

- Comparative effectiveness research: what is it and why is it important?

*Gary H. Lyman, MD, MPH*

- Comparative effectiveness research to address uncertainties in oncology practice

*Neal J. Meropol, MD*

- Methods of comparative effectiveness research in oncology

*Jerome Seidenfeld, PhD*

---

**Session Title:** #40: Developing Drugs in Special Populations: Organ Dysfunction Studies

**Session Type:** Education Session

**Date:** Tuesday, June 8

**Location:** E354b

**Time:** 8:00 AM - 9:15 AM

- Renal dysfunction studies

*Daniel Mulkerin, MD*

- Liver dysfunction studies

*Ghassan K. Abou-Alfa, MD*

- Regulatory considerations for organ dysfunction studies

*Shiew-Mei Huang, PhD*

**Session Title:** #42: Early-stage Non-small Cell Lung Cancer: Staging and Primary Treatment

**Session Type:** Education Session

**Date:** Tuesday, June 8

**Location:** E353

**Time:** 8:00 AM - 9:15 AM

- Non-surgical staging of the mediastinum  
*Scott Shofer, MD, PhD*
- Lobectomies for small or non-invasive lung cancers: Going, going, gone?  
*Harvey I. Pass, MD*
- Outcome of early stage NSCLC treated with SBRT  
*Andrea Bezjak, MD*

**Session Title:** #83: Omics: Toward Personalizing Care

**Session Type:** Education Session

**Date:** Tuesday, June 8

**Location:** S100a

**Time:** 8:00 AM - 9:15 AM

- The genomics and genetics of melanoma  
*Kate Nathanson, MD, FACP*
- From high throughput transcriptomics to personalized cancer care  
*Dimitrios Spentzos, MD*
- Proteomics pathway analysis for tumor classification and therapy (focus on breast and ovary)  
*Gordon B. Mills, MD*

**Session Title:** #90: Localized Prostate Cancer: Reducing Mortality and Burden of Therapy

**Session Type:** Education Session

**Date:** Tuesday, June 8

**Location:** E Arie Crown Theater

**Time:** 8:00 AM - 9:15 AM

- Everything you need to know about prostate cancer screening  
*Andrew J. Stephenson, MD*

- What is "active surveillance" and what is its role in management today?

*Laurence Klotz, MD, FRCSC*

---

**Session Title:** #92: Selection of Endpoints in Clinical Trials: From Bench to Trials to Practice

**Session Type:** Education Session

**Date:** Tuesday, June 8

**Location:** S100b

**Time:** 8:00 AM - 9:15 AM

- Use of molecular markers as surrogate endpoints in clinical trials

*Carlos Cordon-Cardo, MD, PhD*

- Design of Clinical Trials to Achieve Meaningful Results

*Mary W Redman, PhD*

- Translating Clinical Trial Results into Societal Benefit: The Role of Population-based Outcome Studies

*Christopher M. Booth, MD*

---

**Session Title:** #128: Debates in Adjuvant Therapy: Chemotherapy versus Observation for Node-negative Non-small Cell Lung Cancer and Radiotherapy versus Observation for Node-positive Non-small Cell Lung Cancer

**Session Type:** Clinical Problems in Oncology Session

**Date:** Tuesday, June 8

**Location:** E451a

**Time:** 8:00 AM - 9:15 AM

- Is There a Role for Adjuvant Chemotherapy for Node Negative NSCLC?

*Katherine Pisters, MD*

- Neo-Adjuvant Versus Adjuvant Chemotherapy for Early Stage NSCLC; Does Pre versus Post Really Matter?

*Heather A. Wakelee, MD*

- When Should One Consider Adjuvant Radiotherapy for Resected NSCLC?

*Christopher Ryan Kelsey, MD*

**Session Title:** #177: Gastrointestinal (Colorectal) Cancer

**Session Type:** Poster Discussion Session

**Date:** Tuesday, June 8

**Location:** S403

**Time:** 8:00 AM - 12:00 PM

- Gastrointestinal (Colorectal) Cancer

*John S. Kauh, MD*

- Gastrointestinal (Colorectal) Cancer

*Richard Herrmann, MD*

1 #3509-A randomized trial comparing local recurrence (LR) rates between short-course (SC) and long-course (LC) preoperative radiotherapy (RT) for clinical T3 rectal cancer: An intergroup trial (TROG, AGITG, CSSANZ, RACS).

*Sam Ngan*

2 #3510-Pathologic complete response (pCR) to neoadjuvant chemoradiation (CRT) of uT2uN0 rectal cancer (RC) treated by local excision (LE): Results of the ACOSOG Z6041 trial.

*Julio Garcia-Aguilar*

3 #3511-Neoadjuvant FOLFOX-bev, without radiation, for locally advanced rectal cancer.

*Deborah Schrag, MD*

4 #3512-Identification of localized rectal cancer (RC) patients (pts) who may not require preoperative (preop) chemoradiation (CRT).

*Desamparados Roda*

- Discussion

*Bruce D. Minsky, MD*

5 #3513-Independent validation of a prognostic genomic profile (ColoPrint) for stage II colon cancer (CC) patients .

*Robert Rosenberg*

6 #3514-Genome-wide association study for germline prognostic markers in colorectal cancer.

*Axel Walther*

7 #3515-Metachronous colorectal cancer in mismatch repair gene mutation carriers: The advantage of more extensive surgery.

*Susan Parry*

8 #3516-Use of a combination of prognostic (prog) gene index and nodal status to identify a subset of stage II and III colon cancer patients (pts) who may not need oxaliplatin (ox)-containing adjuvant chemotherapy.

9 #3517-Value of mismatch repair, *KRAS*, and *BRAF* mutations in predicting recurrence and benefits from chemotherapy in colorectal cancer.

*Gordon Hutchins*

10 #3518-Analysis of time-dependent patterns of treatment effect and failure to explain the predictive role of deficient mismatch repair (dMMR) in stage II and III colon cancer (CC).

*George P. Kim*

11 #3519-DNA mismatch repair status and site of tumor recurrence in stage II and III colon cancers treated in 5-fluorouracil-based adjuvant therapy trials.

*Frank Sinicrope, MD*

- Discussion

*Patrick Johnston, MD, PhD*

12 #3520-Impact of young (Y) age on efficacy and safety in advanced colorectal cancer (aCRC): A pooled analysis examining 6,286 patients (pts) from nine first-line phase III chemotherapy (CT) trials.

*C. D. Blanke, MD*

13 #3521-Efficacy findings from a randomized phase III trial of capecitabine plus oxaliplatin versus bolus 5-FU/LV for stage III colon cancer (NO16968): No impact of age on disease-free survival (DFS).

*Daniel G. Haller*

14 #3522-FOLFOX4 as adjuvant therapy in elderly patients (pts) with colon cancer (CC): Subgroup analysis of the MOSAIC trial.

*Christophe Tournigand*

15 #3523-Benefits and adverse events (AEs) in younger (Y) (age <50) versus older patients (pts) receiving adjuvant chemotherapy (AT) for colon cancer (CC): Findings from the 33,574 pt ACCENT dataset.

*Daniel J. Sargent, PhD*

16 #3524-Efficacy of FOLFOX4 as adjuvant therapy in stage II colon cancer (CC): A new analysis of the MOSAIC trial according to risk factors.

*Luis Teixeira*

17 #3525-Intermittent versus continuous oxaliplatin-fluoropyrimidine (Ox-Fp) chemotherapy (CT) in first-line treatment of patients (pts) with advanced colorectal cancer (aCRC): Predictive factors (PF), quality of life (QL), and final efficacy results from the MRC COIN trial.

*Richard A Adams, BMBS*

18 #3527-A phase II trial of 5-fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) chemotherapy plus bevacizumab (bev) for patients (pts) with unresectable stage IV colon cancer and a synchronous asymptomatic primary tumor: Results of NSABP C-10.

*Laurence E. McCahill*

19 #3528^--Randomized, open-label, phase III study of panitumumab (pmab) with FOLFOX4 versus FOLFOX4 alone as first-line treatment (tx) for metastatic colorectal cancer (mCRC): Efficacy by skin toxicity (ST).

*Jean-Yves Douillard*

20 #3529^--Randomized, open-label, phase III study of panitumumab (pmab) with FOLFIRI versus FOLFIRI alone as second-line treatment (tx) in patients (pts) with metastatic colorectal cancer (mCRC): Efficacy by skin toxicity (ST).

*Timothy Jay Price*

21 #3530-Safety analysis of a randomized phase II trial of hedgehog pathway inhibitor (HPI) GDC-0449 versus placebo with FOLFOX or FOLFIRI and bevacizumab in patients with previously untreated metastatic colorectal cancer (mCRC).

*Johanna C. Bendell, MD*

22 #3531-Final results of a randomized phase II study of perifosine in combination with capecitabine (P-CAP) versus placebo plus capecitabine (CAP) in patients (pts) with second- or third-line metastatic colorectal cancer (mCRC).

*Donald Anthony Richards*

23 #3532-A randomized, phase IIb study of sunitinib plus 5-fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) versus bevacizumab plus mFOLFOX6 as first-line treatment for metastatic colorectal cancer (mCRC): Interim results.

*J. Randolph Hecht*

24 #3533-DUX study: A phase II study of evaluating dual targeting of the EGFR using the combination of cetuximab and erlotinib in patients with chemotherapy refractory metastatic colorectal cancer.

*Andrew James Weickhardt*

25 #3535-Phase II trial of bevacizumab (B) plus everolimus (E) for refractory metastatic colorectal cancer (mCRC).

*Ivy Altomare*

- Discussion

*Wells A. Messersmith, MD*

**Session Title:** #185: Lung Cancer - Local-Regional and Adjuvant Therapy

**Session Type:** Poster Discussion Session

**Date:** Tuesday, June 8

**Location:** E450b

**Time:** 8:00 AM - 12:00 PM

- Lung Cancer - Local-Regional and Adjuvant Therapy

*Corey J. Langer, MD*

- Lung Cancer - Local-Regional and Adjuvant Therapy

*Joseph Kamel Salama, MD*

1 #7008-Impact of *KRAS* mutations on adjuvant carboplatin/paclitaxel in surgically resected stage IB NSCLC: CALGB 9633.

*Marzia Capelletti*

2 #7009-Initial results of LC-MAP: An institutional program to routinely profile tumor specimens for the presence of mutations in targetable pathways in all patients with lung adenocarcinoma.

*Mark G. Kris*

3 #7010-Association of genetic variations in DNA-methyltransferases, histone-methyltransferases, and methylated DNA-binding proteins with recurrence and survival in early-stage non-small cell lung cancer treated with surgery alone or surgery and chemotherapy.

*Klaus Wolfgang Wagner*

4 #7011-Impact of *EGFR* and *KRAS* mutations on survival in 1,000 patients with resected lung adenocarcinoma.

*Sandra P. D'Angelo*

5 #7012-Clinical relevance of insulin regulatory pathways in non-small cell lung cancer (NSCLC) progression.

*Yanis Bellil*

6 #7013-*KRAS* and *EGFR* mutations in the molecular epidemiology of NSCLC: Interim analysis of S0424.

*Philip C. Mack*

- Discussion: Biomarkers in Early Stage NSCLC: Has the future arrived?

*John V Heymach, MD, PhD*

7 #7014-Treatment of the elderly when cure is the goal: The influence of age on treatment selection and efficacy for stage III non-small cell lung cancer (NSCLC).

*Linda E. Coate*

8 #7015-A multinational pooled analysis of 434 cases of stage I non-small cell lung cancer (NSCLC) treated with volumetrically image-guided (VICRT)

9 #7016-Thoracic radiation therapy in locally advanced NSCLC patients (pts) with EGFR mutations.

*Raymond H. Mak*

- Discussion: New Directions for Radiotherapy in NSCLC

*Jeffrey Bogart, MD*

10 #7017-Utilization of adjuvant therapy among completely resected non-small cell lung cancer (NSCLC) patients in the National Comprehensive Cancer Network (NCCN) outcomes database project.

*Carrie Zornosa, MS*

11 #7018-Adoption of adjuvant chemotherapy for non-small cell lung cancer: A population-based outcomes study.

*Christopher M. Booth, MD*

12 #7019-A phase III adjuvant vinorelbine plus cisplatin (NP) versus NP plus endostar (NPE) in patients (pts) with completely resected stage IB-IIIA non-small cell lung cancer (NSCLC): An interim preliminary result.

*He Jie*

13 #7020-IFCT-GFPC-0701 MAPS trial, a multicenter randomized phase II/III trial of pemetrexed-cisplatin with or without bevacizumab in patients with malignant pleural mesothelioma.

*Gerard Zalcman*

- Discussion: Surgical Perspective on Systemic Therapy for NSCLC and Mesothelioma

*William Roy Smythe, MD*

14 #7021-Validation of the lung cancer staging system revisions using a large prospective clinical trial database (ACOSOG Z0030).

*Juan J. Fibla*

15 #7022-The impact of stage migration on survival after resection in the UICC 7 TNM classification of lung cancer.

*Jan P. Van Meerbeeck*

16 #7023-Prognostic significance of the number of tumor (+) N2 nodes in N2 stage IIIA non-small cell lung cancer after curative resection.

*Changhoon Yoo*

17 #7024-RTOG 0229: A phase II trial of neoadjuvant therapy with concurrent chemotherapy and high-dose radiotherapy (XRT) followed by resection and consolidative therapy for LA-NSCLC.

*Mohan Suntharalingam, MD*

18 #7025-Seven-year follow-up of preoperative chemoradiotherapy in superior sulcus tumor: Report of a Japan Clinical Oncology Group Trial (JCOG9806).

*Masahiro Tsuboi*

19 #7026-Treatment for superior sulcus tumors (SST): Effect of surgery first followed by adjunct concurrent chemoradiotherapy on survival of patients with marginally resectable SST.

*Ritsuko Komaki*

- Discussion: Alternative Approaches to Advanced Resectable NSCLC

*Jessica S. Donington, MD*

---

**Session Title:** #189: Patient and Survivor Care

**Session Type:** Poster Discussion Session

**Date:** Tuesday, June 8

**Location:** E450a

**Time:** 8:00 AM - 12:00 PM

- Patient and Survivor Care

*Amy Pickar Abernethy, MD*

- Patient and Survivor Care

*Janet Lee Abrahm, MD*

1 #9017-Evaluation of a urea/lactic acid-based topical keratolytic agent (ULABTKA) for prevention of capecitabine-induced hand and foot syndrome (HFS): NCCTG trial N05C5.

*Sherry L Wolf*

2 #9018-Using the Skindex-16 and CTCAE to assess rash symptoms: Results of a pooled-analysis (N0993).

*Pamela J Atherton*

3 #9019-CYTAR: A randomized clinical trial evaluating the preventive effect of doxycycline on erlotinib-induced folliculitis in non-small cell lung cancer patients.

*Gael Deplanque*

4 #9020-Olanzapine versus aprepitant for the prevention of chemotherapy-induced nausea and vomiting (CINV): A randomized phase III trial.

*Rudolph M. Navari*

5 #9021-Phase III randomized double-blind study of single-dose fosaprepitant for prevention of cisplatin-induced nausea and vomiting.

*Steven M. Grunberg, MD*

- Discussion

*Michael Fisch, MD, MPH*

7 #9023-A randomized crossover trial of venlafaxine (V) versus gabapentin (G) for hot flashes (HF) in breast cancer survivors.

*Louise Bordeleau*

8 #9024-A phase III randomized, double-blind, placebo-controlled study of pilocarpine for vaginal dryness: NCCTG study N04CA.

*Charles L. Loprinzi, MD*

9 #9025-Phase II study of gonadotropin-releasing hormone analogue for ovarian function preservation in hematopoietic stem cell transplantation patients.

*Yee Chung Cheng*

10 #9026-Value of early referral to improve fertility preservation outcomes in women with breast cancer.

*Kutluk Oktay*

11 #9027-Impact of 12 months of androgen-deprivation therapy (ADT) on cognitive function in men with nonmetastatic prostate cancer (PC): A matched cohort study.

*Shabbir M.H. Alibhai, MD, MSc*

12 #9028-The incidence of potential medication interactions including herbs and supplements among breast and prostate cancer patients during and after systemic anticancer therapy.

*Nancy Kwon*

- Discussion

*Vered Stearns, MD*

13 #9029-Pilot trial of a patient-specific cutaneous electrostimulation device (MC5-A Calmare) for chemotherapy-induced peripheral neuropathy.

*Thomas J. Smith, MD*

14 #9030-Signs and symptoms of peripheral neuropathy in adult survivors of childhood acute lymphoblastic leukemia (ALL): Associations with physical performance and chemotherapy doses.

*Kirsten K. Ness*

15 #9031-Comparison of in-dwelling catheters and talc pleurodesis in the management of malignant pleural effusions.

*Todd L. Demmy, MD, FACS*

16 #9032-Use of postoperative venous thromboembolism to predict disease-specific survival in cancer patients.

*Rebecca Ann C Auer*

17 #9033-Comparison of venous thromboemboli (VTE) incidence in cancer patients who are on statin therapy versus those not on statin therapy.

*Thomas A Giever, DO, MBA*

18 #9034-Screening for cardiac dysfunction and cardiovascular risk factors in childhood cancer survivors using the Children's Oncology Group (COG) long-term follow-up (LTFU) guidelines.

*Saro Armenian*

- Discussion

*Charles L. Loprinzi, MD*

19 #9035-Quality of life and symptoms in long-term survivors (LTS) of colorectal cancer (CRC): Results from NSABP protocol LTS-01.

*Hiroko Kunitake*

20 #9036-Quality-of-life results of an EORTC phase III randomized trial of adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases of solid tumors.

*Riccardo Soffietti*

21 #9037-Cancer outcomes at end of life in Michigan.

*May Darwish-Yassine*

22 #9038-Predictors of patient misunderstanding of the goals of care at initiation of chemotherapy.

*Inga Tolin Lennes*

23 #9039-Hope, optimism, and survival in a randomized trial of first-line chemotherapy for patients with metastatic colorectal cancer.

*Penelope Schofield*

24 #9040-Patient-reported outcomes for determining prognostic groups in veterans with advanced cancer.

*Victor Tsu-Shih Chang*

25 #9041-Symptom burden in cancer survivors one year after diagnosis: A report from the American Cancer Society's studies of cancer survivors.

*Qiuling Shi*

- Discussion

*Frederick J. Meyers, MD*

**Session Title:** #191: Sarcoma

**Session Type:** Poster Discussion Session

**Date:** Tuesday, June 8

**Location:** S103

**Time:** 8:00 AM - 12:00 PM

- Sarcoma

*Mark Agulnik, MD*

- Sarcoma

*Anette Duensing, MD*

1 #10009-Results of a Sarcoma Alliance for Research through Collaboration (SARC) phase II trial of dasatinib in previously treated, high-grade, advanced sarcoma.

*Scott Schuetze*

2 #10010-Advanced phase I/II evaluation of tumor-targeted gene delivery: Intravenous retrovector encoding mutant anticyclin G1 as stand-alone therapy for chemotherapy-resistant bone and soft tissue sarcoma.

*Kristen N. Ganjoo*

3 #10011-Imatinib in the treatment of tenosynovial giant-cell tumor and pigmented villonodular synovitis.

*Vinod Ravi*

4 #10012-Imatinib mesylate for the treatment of locally advanced and/or metastatic pigmented villonodular synovitis/tenosynovial giant cell tumor (PVNS/TGCT).

*Philippe Alexandre Cassier*

5 #10013-Activity of sorafenib against desmoid tumor/deep fibromatosis (DT/DF).

*Mrinal M. Gounder, MD*

6 #10014-Sunitinib malate (SM) in alveolar soft part sarcoma (ASPS).

*Elena Palassini*

- Discussion

*Ian Robert Judson, MD*

7 #10015-Phase II trial of nilotinib as third-line therapy for gastrointestinal stromal tumor (GIST) patients in Japan.

*Toshirou Nishida, MD, PhD, FACS*

8 #10016-Nilotinib for patients with advanced GIST who failed imatinib and sunitinib: Negative effect of prior major gastrectomy on exposure to nilotinib.

9 #10017^--Phase III trial of nilotinib in patients with advanced gastrointestinal stromal tumor (GIST): First results from ENEST g3.

*Peter Reichardt*

10 #10018-Validation of Joensuu risk criteria for primary resectable gastrointestinal stromal tumors.

*Piotr Rutkowski*

11 #10019-Correlation of the topography of *KIT* exon 11 mutation with primary GIST location and predictive value for PFS in patients with advanced GIST: Results from the BFR14 randomized phase III trial of the French Sarcoma Group.

*Jean-Yves Blay, MD, PhD*

12 #10020-Activity of GDC-0941, an inhibitor of phosphoinositol 3 kinase (PI3K), in gastrointestinal stromal tumor (GIST) xenograft and duration of response after discontinuation of treatment in combination with imatinib.

*Giuseppe Floris*

- Discussion

*Margaret von Mehren, MD*

13 #10021-Adjuvant treatment of high-risk primary uterine leiomyosarcoma with gemcitabine/docetaxel (GT), followed by doxorubicin (D): Results of phase II multicenter trial SARC005.

*Martee Leigh Hensley, MD, MSc*

14 #10022-Long-term follow-up of patients treated with neoadjuvant chemotherapy and radiotherapy for large, extremity soft tissue sarcomas.

*John Thomas Mullen*

15 #10023-A phase II study of neoadjuvant bevacizumab and radiation therapy for resectable soft tissue sarcomas.

*Sam S. Yoon*

16 #10024-Phase I study of sorafenib plus ifosfamide in patients with advanced soft tissue and bone sarcoma: A Spanish Group for Research on Sarcomas (GEIS) study.

*Xavier Garcia del Muro*

17 #10025-Efficacy and toxicity of sorafenib monotherapy in patients with advanced soft tissue sarcoma failing anthracycline-based chemotherapy.

*Alexia Bertuzzi*

18 #10026-A stratified phase II trial investigating sorafenib (SORA) in patients (pts) with metastatic or locally advanced angiosarcoma (AS).

*Nicolas Penel*

- Discussion

*Rashmi Chugh, MD*

19 #10027-Trabectedin (Tr) as single agent for advanced soft tissue sarcomas (STS) failing standard of care: Interim analysis of 1,400 patients (pts) in an expanded access program study.

*Brian Louis Samuels*

20 #10028-Trabectedin (Tr) in the treatment of advanced uterine leiomyosarcomas (U-LMS): Results of a pooled analysis of five single-agent phase II studies using the recommended dose.

*Ian Robert Judson, MD*

21 #10029-Outcomes of patients (pts) with advanced soft-tissue sarcomas (STS) treated in clinical trials (CTs) versus expanded access programs (EAPs): A decade of experience with single-agent trabectedin (Tr).

*George D. Demetri*

22 #10030-Trabectedin (T) in advanced, pretreated synovial sarcomas (SS): A retrospective analysis of 39 patients (pts) from three European institutions.

*Palma Dileo*

23 #10031-Activity of eribulin mesylate (E7389) in patients with soft tissue sarcoma (STS): Phase II studies of the European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group (EORTC 62052).

*Patrick Schoffski, MD, MPH*

24 #10032-Risk of relapse with imatinib (IM) discontinuation at 5 years in advanced GIST patients: Results of the prospective BFR14 randomized phase III study comparing interruption versus continuation of IM at 5 years of treatment: A French Sarcoma Group study.

*Isabelle Ray-Coquard*

25 #10033-Time to onset of progression after imatinib interruption and outcome of patients with advanced GIST: Results of the BFR14 prospective French Sarcoma Group randomized phase III trial.

*Axel Le Cesne*

- Discussion

*James E. Butrynski, MD*

**Session Title:** #332: Advancing Pain and Palliative Care Globally for Patients with Cancer

**Session Type:** Special Session

**Date:** Tuesday, June 8

**Location:** S504

**Time:** 9:00 AM - 12:00 PM

- Advancing Pain and Palliative Care Globally for Patients with Cancer

*Jamie H. Von Roenn, MD*

- Global Access to Cancer Pain Initiative

*David Hill, PhD*

- International Activities in Cancer and Palliative Care

*Joe B. Harford, PhD*

- International Drug Policy and Cancer Pain Control

*James F. Cleary, MD*

- International Education Activities in Palliative Care

*Frank Douglas Ferris, MD*

- Panel: Palliative Care and Cancer in the Future

*Kathleen M. Foley, MD*

- Panel: Palliative Care and Cancer in the Future

*Aziza T. Shad, MD*

- Panel: Palliative Care and Cancer in the Future

*Eduardo Bruera, MD*

**Session Title:** #25: Closing the Loop: Evidence, Guidelines, Reporting, and Quality

**Session Type:** Education Session

**Date:** Tuesday, June 8

**Location:** S100a

**Time:** 9:30 AM - 10:45 AM

- Quality reporting, measurement and feedback

*Craig Earle, MD*

- Barriers to quality improvement initiatives

*Sandra L. Wong, MD, MS*

- Distilling research and evidence into opportunities for quality improvement

**Session Title:** #95: Supportive Care for Patients with Non-small Cell Lung Cancer

**Session Type:** Education Session

**Date:** Tuesday, June 8

**Location:** E353

**Time:** 9:30 AM - 10:45 AM

- Management of dyspnea and pleural effusion in patients with lung cancer

*David Feller-Kopman, MD*

- Ancillary therapy for bone mets in the age of bisphosphonates

*Vera Hirsh, MD*

- Management of brain metastases in lung cancer patients.

*Minesh P. Mehta, MD*

**Session Title:** #145: Breast Cancer - Metastatic

**Session Type:** Oral Abstract Session

**Date:** Tuesday, June 8

**Location:** E Hall D1

**Time:** 9:30 AM - 12:30 PM

- Breast Cancer - Metastatic

*Herve R. Bonnefoi, MD*

- Breast Cancer - Metastatic

*Elizabeth Claire Dees, MD*

- #CRA1004<sup>^</sup>-A phase III study (EMBRACE) of eribulin mesylate versus treatment of physician's choice in patients with locally recurrent or metastatic breast cancer previously treated with an anthracycline and a taxane.

*Christopher Twelves*

- Discussion

*Harold J. Burstein, MD, PhD*

- #LBA1010-Sunitinib (SU) in combination with docetaxel (D) vs D alone for the first-line treatment of advanced breast cancer (ABC)

*Jonas Bergh, MD, PhD*

- #LBA1011-Phase 3 Trial of Sunitinib (SU) in Combination with Capecitabine (C) vs C in Previously Treated Advanced Breast Cancer (ABC)

*John Crown*

- #1005-A meta-analysis of overall survival data from three randomized trials of bevacizumab (BV) and first-line chemotherapy as treatment for patients with metastatic breast cancer (MBC).

*Joyce O'Shaughnessy*

- #1006-Simple oral therapy with capecitabine (CAPE) and cyclophosphamide (CPA) for metastatic breast cancer (MBC).

*Anne F. Schott, MD*

- Discussion

*Hope S. Rugo, MD*

- #1007-Tissue confirmation of disease recurrence in patients with breast cancer: Pooled analysis of two large prospective studies.

*Eitan Amir*

- #CRA1008-Should liver metastases of breast cancer be biopsied to improve treatment choice?

*Marzia Adelia Locatelli*

- #1009-Discordance in hormone receptor status in breast cancer during tumor progression.

*Eva Karlsson, MD*

- Discussion

*Andrea L. Richardson, MD, PhD*

---

**Session Title:** #148: Developmental Therapeutics - Clinical Pharmacology and Immunotherapy

**Session Type:** Oral Abstract Session

**Date:** Tuesday, June 8

**Location:** E354a

**Time:** 9:30 AM - 12:30 PM

- Developmental Therapeutics - Clinical Pharmacology and Immunotherapy

*Tyler J. Curiel, MD*

- #2506-Safety and antitumor activity of biweekly MDX-1106 (Anti-PD-1, BMS-936558/ONO-4538) in patients with advanced refractory malignancies.

*Mario Sznol*

- #2507-A Cancer Research UK phase I study evaluating safety, tolerability, and biological effects of chimeric anti-CD40 monoclonal antibody (MAb), Chi Lob 7/4.

*Peter W. M. Johnson*

- #2508-Phase I study of anti-CD25 mab daclizumab to deplete regulatory T cells prior to telomerase/survivin peptide vaccination in patients (pts) with metastatic breast cancer (MBC).

*Andrew J. Rech, BS*

- Discussion

*Tyler J. Curiel, MD*

- #2509-Cell therapy with EBV-specific cytotoxic T-lymphocytes for patients with nasopharyngeal carcinoma.

*Patrizia Comoli*

- #2510-Immunotherapy in high-risk chemotherapy-resistant patients with metastatic solid tumors and hematologic malignancies using intentionally mismatched donor lymphocytes activated with rIL-2: A phase II study.

*Shimon Slavin*

- #2511-Vaccination with DC/RCC fusions following cytoreductive nephrectomy.

*David Avigan*

- #2512-A phase I study of bevacizumab in combination with sunitinib, sorafenib, erlotinib plus cetuximab, and trastuzumab plus lapatinib.

*Gerald Steven Falchook*

- #2513-First-line chemoimmunotherapy in metastatic breast carcinoma: Effect of a combination of paclitaxel and LAG-3-ig (IMP321), a novel MHC class II agonist, on T-cell responses and antitumor activity.

*Maya Gutierrez*

- #2514-Pharmacodynamic response in phase I combination study of ABT-888 and topotecan in adults with refractory solid tumors and lymphomas.

*Jiuping Jay Ji, PhD*

- Discussion

*Mark J. Ratain, MD*

**Session Title:** #153: Genitourinary Cancer (Testes, Kidney, and Bladder)

**Session Type:** Oral Abstract Session

**Date:** Tuesday, June 8

**Location:** E Arie Crown Theater

**Time:** 9:30 AM - 12:30 PM

- Genitourinary Cancer (Testes, Kidney, and Bladder)

*Hvung Lae Kim, MD*

- Genitourinary Cancer (Testes, Kidney, and Bladder)

*Deborah Ann Bradley, MD*

- #4512-A randomized phase III study comparing standard dose BEP with sequential high-dose cisplatin, etoposide, ifosfamide (VIP) plus stem cell support in males with poor prognosis germ cell cancer (GCC): An intergroup study of EORTC, GTCSSG, and Grupo Germinal (EORTC 30974).

*Gedske Daugaard*

- #4513-Conventional-dose versus high-dose chemotherapy in relapsed or refractory male germ-cell tumors: A retrospective study in 1,594 patients.

*Anja Lorch*

- Discussion: Treatment intensity and outcome in germ cell tumors

*Derek Raghavan, MD, PhD*

- #4514-The high-dose aldesleukin (HD IL-2) "SELECT" trial in patients with metastatic renal cell carcinoma (mRCC).

*David F. McDermott, MD*

- #4530-A phase II study of bevacizumab (B) and high-dose aldesleukin (IL-2) in patients (p) with metastatic renal cell carcinoma (mRCC): A Cytokine Working Group study (CWGS).

*Uday B. Dandamudi*

- #4516-Can the combination of temsirolimus and bevacizumab improve the treatment of metastatic renal cell carcinoma (mRCC)? Results of the randomized TORAVA phase II trial.

*Bernard J. Escudier*

- Discussion: Metastatic renal cell carcinoma: which way forward?

*Dror Michaelson, MD, PhD*

- #4517-Results of a phase III randomized trial of synchronous chemoradiotherapy (CRT) compared to radiotherapy (RT) alone in muscle invasive bladder cancer (MIBC) (BC2001 CRUK/01/004).

*Nicholas David James*

- #LBA4518-Randomized phase III trial comparing adjuvant paclitaxel/gemcitabine/cisplatin (PGC) to observation in patients with resected invasive bladder cancer: Results of the SOGUG (Spanish Oncology Genitourinary Group) 99/01 study.

*Luis G Paz-Ares*

- #LBA4519-Randomized phase II/III trial comparing gemcitabine/carboplatin (GC) and methotrexate/carboplatin/vinblastine (M-CAVI) in patients (pts) with advanced urothelial cancer (UC) unfit for cisplatin based chemotherapy (CHT): Phase III results of EORTC study 30986.

*Maria De Santis*

- Discussion: Is systemic therapy impacting progress in urothelial cancer?

*Cora N. Sternberg, MD*

---

**Session Title:** #12: Angiogenesis: Where Do We Go from Here?

**Session Type:** Education Session

**Date:** Tuesday, June 8

**Location:** S100b

**Time:** 9:45 AM - 11:00 AM

- Genomic Approaches for Vascular Target Identification in Solid Tumors

*George Coukos, MD, PhD*

- Contrasting effects of VEGF pathway targeting antibodies and TKIs on microscopic versus advanced metastatic disease

*Robert S Kerbel, PhD*

- Targeting tumor angiogenesis - what have learned so far?

*Lee M Ellis, MD, FACS*

---

**Session Title:** #45: Even Patients with Liver Dysfunction Can Get Chemotherapy!

**Session Type:** Education Session

**Date:** Tuesday, June 8

**Location:** E354b

**Time:** 9:45 AM - 11:00 AM

- Understanding assessment of liver function and viral hepatitis for the medical oncologist.

*Lewis R. Roberts, PhD, MBChB*

- Understanding the importance of hepatic function and dysfunction in metabolism of anticancer agents Delivering chemotherapy to the patient with liver dysfunction.

*Timothy W. Synold, PharmD*

- Management of dosing and side effects of specific chemotherapeutic agents.

**Session Title:** #138: The Best Treatment for Hepatic Metastases: What Is the Evidence?

**Session Type:** Clinical Problems in Oncology Session

**Date:** Tuesday, June 8

**Location:** E451a

**Time:** 9:45 AM - 11:00 AM

- Review the data supporting chemotherapy and molecular targeted therapy in management of hepatic metastases.

*Heinz-Josef Lenz, MD*

- Evidence for patient benefit using surgical and/or ablation for hepatic metastases.

*Bryan M. Clary, MD*

- The incorporation of conventional and stereotactic body radiation therapy into the treatment of hepatic metastases.

*Christopher Willett, MD*

**Session Title:** #264: Imaging Informatics and Optimizing Imaging in Cancer Diagnosis: An ASCO and RSNA Joint Session

**Session Type:** Special Session

**Date:** Tuesday, June 8

**Location:** S404

**Time:** 9:45 AM - 11:00 AM

- Introduction

*Douglas W. Blayney, MD*

- Imaging Informatics and How it Can Help Improve Quality of Care in Cancer Patients

*Paul Chang, MD, FSIIM*

- Oncologic Imaging: Which Exam to Order, and How to Integrate the Results?

*David M. Panicek, MD, FACR*

- Closing Comments

*Richard Baron, MD, FACR*

**Session Title:** #244: Gastrointestinal (Colorectal) Cancer

**Session Type:** Poster Discussion Session

**Date:** Tuesday, June 8

- Gastrointestinal (Colorectal) Cancer

*John S. Kauh, MD*

- Gastrointestinal (Colorectal) Cancer

*Richard Herrmann, MD*

1 #3509-A randomized trial comparing local recurrence (LR) rates between short-course (SC) and long-course (LC) preoperative radiotherapy (RT) for clinical T3 rectal cancer: An intergroup trial (TROG, AGITG, CSSANZ, RACS).

*Sam Ngan*

2 #3510-Pathologic complete response (pCR) to neoadjuvant chemoradiation (CRT) of uT2uN0 rectal cancer (RC) treated by local excision (LE): Results of the ACOSOG Z6041 trial.

*Julio Garcia-Aguilar*

3 #3511-Neoadjuvant FOLFOX-bev, without radiation, for locally advanced rectal cancer.

*Deborah Schrag, MD*

4 #3512-Identification of localized rectal cancer (RC) patients (pts) who may not require preoperative (preop) chemoradiation (CRT).

*Desamparados Roda*

- Discussion

*Bruce D. Minsky, MD*

5 #3513-Independent validation of a prognostic genomic profile (ColoPrint) for stage II colon cancer (CC) patients .

*Robert Rosenberg*

6 #3514-Genome-wide association study for germline prognostic markers in colorectal cancer.

*Axel Walther*

7 #3515-Metachronous colorectal cancer in mismatch repair gene mutation carriers: The advantage of more extensive surgery.

*Susan Parry*

8 #3516-Use of a combination of prognostic (prog) gene index and nodal status to identify a subset of stage II and III colon cancer patients (pts) who may not need oxaliplatin (ox)-containing adjuvant chemotherapy.

*K. L. Pogue-Geile*

9 #3517-Value of mismatch repair, *KRAS*, and *BRAF* mutations in predicting recurrence and benefits from chemotherapy in colorectal cancer.

*Gordon Hutchins*

10 #3518-Analysis of time-dependent patterns of treatment effect and failure to explain the predictive role of deficient mismatch repair (dMMR) in stage II and III colon cancer (CC).

*George P. Kim*

11 #3519-DNA mismatch repair status and site of tumor recurrence in stage II and III colon cancers treated in 5-fluorouracil-based adjuvant therapy trials.

*Frank Sinicrope, MD*

- Discussion

*Patrick Johnston, MD, PhD*

12 #3520-Impact of young (Y) age on efficacy and safety in advanced colorectal cancer (aCRC): A pooled analysis examining 6,286 patients (pts) from nine first-line phase III chemotherapy (CT) trials.

*C. D. Blanke, MD*

13 #3521-Efficacy findings from a randomized phase III trial of capecitabine plus oxaliplatin versus bolus 5-FU/LV for stage III colon cancer (NO16968): No impact of age on disease-free survival (DFS).

*Daniel G. Haller*

14 #3522-FOLFOX4 as adjuvant therapy in elderly patients (pts) with colon cancer (CC): Subgroup analysis of the MOSAIC trial.

*Christophe Tournigand*

15 #3523-Benefits and adverse events (AEs) in younger (Y) (age <50) versus older patients (pts) receiving adjuvant chemotherapy (AT) for colon cancer (CC): Findings from the 33,574 pt ACCENT dataset.

*Daniel J. Sargent, PhD*

16 #3524-Efficacy of FOLFOX4 as adjuvant therapy in stage II colon cancer (CC): A new analysis of the MOSAIC trial according to risk factors.

*Luis Teixeira*

17 #3525-Intermittent versus continuous oxaliplatin-fluoropyrimidine (Ox-Fp) chemotherapy (CT) in first-line treatment of patients (pts) with advanced colorectal cancer (aCRC): Predictive factors (PF), quality of life (QL), and final efficacy results from the MRC COIN trial.

*Richard A Adams, BMBS*

18 #3527-A phase II trial of 5-fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) chemotherapy plus bevacizumab (bev) for patients (pts) with unresectable stage IV colon cancer and a synchronous asymptomatic primary tumor: Results of NSABP C-10.

*Laurence E. McCahill*

19 #3528^-Randomized, open-label, phase III study of panitumumab (pmab) with FOLFOX4 versus FOLFIRI as first-line treatment (tx) for metastatic colorectal cancer (mCRC): Efficacy by skin toxicity (ST).

*Jean-Yves Douillard*

20 #3529^-Randomized, open-label, phase III study of panitumumab (pmab) with FOLFIRI versus FOLFOX4 as second-line treatment (tx) in patients (pts) with metastatic colorectal cancer (mCRC): Efficacy by skin toxicity (ST).

*Timothy Jay Price*

21 #3530-Safety analysis of a randomized phase II trial of hedgehog pathway inhibitor (HPI) GDC-0449 versus placebo with FOLFOX or FOLFIRI and bevacizumab in patients with previously untreated metastatic colorectal cancer (mCRC).

*Johanna C. Bendell, MD*

22 #3531-Final results of a randomized phase II study of perifosine in combination with capecitabine (P-CAP) versus placebo plus capecitabine (CAP) in patients (pts) with second- or third-line metastatic colorectal cancer (mCRC).

*Donald Anthony Richards*

23 #3532-A randomized, phase IIb study of sunitinib plus 5-fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) versus bevacizumab plus mFOLFOX6 as first-line treatment for metastatic colorectal cancer (mCRC): Interim results.

*J. Randolph Hecht*

24 #3533-DUX study: A phase II study of evaluating dual targeting of the EGFR using the combination of cetuximab and erlotinib in patients with chemotherapy refractory metastatic colorectal cancer.

*Andrew James Weickhardt*

25 #3535-Phase II trial of bevacizumab (B) plus everolimus (E) for refractory metastatic colorectal cancer (mCRC).

*Ivy Altomare*

- Discussion

*Wells A. Messersmith, MD*

**Session Title:** #256: Patient and Survivor Care

**Session Type:** Poster Discussion Session

**Date:** Tuesday, June 8

**Location:** E353

**Time:** 11:00 AM - 12:00 PM

- Patient and Survivor Care

*Amy Pickar Abernethy, MD*

- Patient and Survivor Care

*Janet Lee Abraham, MD*

1 #9017-Evaluation of a urea/lactic acid-based topical keratolytic agent (ULABTKA) for prevention of capecitabine-induced hand and foot syndrome (HFS): NCCTG trial N05C5.

*Sherry L Wolf*

2 #9018-Using the Skindex-16 and CTCAE to assess rash symptoms: Results of a pooled-analysis (N0993).

*Pamela J Atherton*

3 #9019-CYTAR: A randomized clinical trial evaluating the preventive effect of doxycycline on erlotinib-induced folliculitis in non-small cell lung cancer patients.

*Gael Deplanque*

4 #9020-Olanzapine versus aprepitant for the prevention of chemotherapy-induced nausea and vomiting (CINV): A randomized phase III trial.

*Rudolph M. Navari*

5 #9021-Phase III randomized double-blind study of single-dose fosaprepitant for prevention of cisplatin-induced nausea and vomiting.

*Steven M. Grunberg, MD*

- Discussion

*Michael Fisch, MD, MPH*

7 #9023-A randomized crossover trial of venlafaxine (V) versus gabapentin (G) for hot flashes (HF) in breast cancer survivors.

*Louise Bordeleau*

8 #9024-A phase III randomized, double-blind, placebo-controlled study of pilocarpine for vaginal dryness: NCCTG study N04CA.

*Charles L. Loprinzi, MD*

9 #9025-Phase II study of gonadotropin-releasing hormone analogue for ovarian function preservation in hematopoietic stem cell transplantation patients.

*Yee Chung Cheng*

10 #9026-Value of early referral to improve fertility preservation outcomes in women with breast cancer.

*Kutluk Oktay*

11 #9027-Impact of 12 months of androgen-deprivation therapy (ADT) on cognitive function in men with nonmetastatic prostate cancer (PC): A matched cohort study.

*Shabbir M.H. Alibhai, MD, MSc*

12 #9028-The incidence of potential medication interactions including herbs and supplements among breast and prostate cancer patients during and after systemic anticancer therapy.

*Nancy Kwon*

- Discussion

*Vered Stearns, MD*

13 #9029-Pilot trial of a patient-specific cutaneous electrostimulation device (MC5-A Calmare) for chemotherapy-induced peripheral neuropathy.

*Thomas J. Smith, MD*

14 #9030-Signs and symptoms of peripheral neuropathy in adult survivors of childhood acute lymphoblastic leukemia (ALL): Associations with physical performance and chemotherapy doses.

*Kirsten K. Ness*

15 #9031-Comparison of in-dwelling catheters and talc pleurodesis in the management of malignant pleural effusions.

*Todd L. Demmy, MD, FACS*

16 #9032-Use of postoperative venous thromboembolism to predict disease-specific survival in cancer patients.

*Rebecca Ann C Auer*

17 #9033-Comparison of venous thromboemboli (VTE) incidence in cancer patients who are on statin therapy versus those not on statin therapy.

*Thomas A Giever, DO, MBA*

18 #9034-Screening for cardiac dysfunction and cardiovascular risk factors in childhood cancer survivors using the Children's Oncology Group (COG) long-term follow-up (LTFU) guidelines.

*Saro Armenian*

- Discussion

*Charles L. Loprinzi, MD*

19 #9035-Quality of life and symptoms in long-term survivors (LTS) of colorectal cancer (CRC): Results from NSABP protocol LTS-01.

*Hiroko Kunitake*

20 #9036-Quality-of-life results of an EORTC phase III randomized trial of adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases of solid tumors.

*Riccardo Soffiatti*

21 #9037-Cancer outcomes at end of life in Michigan.

*May Darwish-Yassine*

22 #9038-Predictors of patient misunderstanding of the goals of care at initiation of chemotherapy.

*Inga Tolin Lennes*

23 #9039-Hope, optimism, and survival in a randomized trial of first-line chemotherapy for patients with metastatic colorectal cancer.

*Penelope Schofield*

24 #9040-Patient-reported outcomes for determining prognostic groups in veterans with advanced cancer.

*Victor Tsu-Shih Chang*

25 #9041-Symptom burden in cancer survivors one year after diagnosis: A report from the American Cancer Society's studies of cancer survivors.

*Qiuling Shi*

- Discussion

*Frederick J. Meyers, MD*

---

**Session Title:** #258: Sarcoma

**Session Type:** Poster Discussion Session

**Date:** Tuesday, June 8

**Location:** S100a

**Time:** 11:00 AM - 12:00 PM

- Sarcoma

*Anette Duensing, MD*

- Sarcoma

*Mark Agulnik, MD*

1 #10009-Results of a Sarcoma Alliance for Research through Collaboration (SARC) phase II trial of dasatinib in previously treated, high-grade, advanced sarcoma.

*Scott Schuetze*

2 #10010-Advanced phase I/II evaluation of tumor-targeted gene delivery: Intravenous retrovector encoding mutant anticyclin G1 as stand-alone therapy for chemotherapy-resistant bone and soft tissue sarcoma.

*Kristen N. Ganjoo*

3 #10011-Imatinib in the treatment of tenosynovial giant-cell tumor and pigmented villonodular synovitis.

*Vinod Ravi*

4 #10012-Imatinib mesylate for the treatment of locally advanced and/or metastatic pigmented villonodular synovitis/tenosynovial giant cell tumor (PVNS/TGCT).

*Philippe Alexandre Cassier*

5 #10013-Activity of sorafenib against desmoid tumor/deep fibromatosis (DT/DF).

*Mrinal M. Gounder, MD*

6 #10014-Sunitinib malate (SM) in alveolar soft part sarcoma (ASPS).

*Elena Palassini*

- Discussion

*Ian Robert Judson, MD*

7 #10015-Phase II trial of nilotinib as third-line therapy for gastrointestinal stromal tumor (GIST) patients in Japan.

*Toshirou Nishida, MD, PhD, FACS*

8 #10016-Nilotinib for patients with advanced GIST who failed imatinib and sunitinib: Negative effect of prior major gastrectomy on exposure to nilotinib.

*Kyu-pyo Kim*

9 #10017-Phase III trial of nilotinib in patients with advanced gastrointestinal stromal tumor (GIST): First results from ENEST g3.

*Peter Reichardt*

10 #10018-Validation of Joensuu risk criteria for primary resectable gastrointestinal stromal tumors.

*Piotr Rutkowski*

11 #10019-Correlation of the topography of *KIT* exon 11 mutation with primary GIST location and predictive value for PFS in patients with advanced GIST: Results from the BFR14 randomized phase III trial of the French Sarcoma Group.

*Jean-Yves Blay, MD, PhD*

12 #10020-Activity of GDC-0941, an inhibitor of phosphoinositol 3 kinase (PI3K), in gastrointestinal stromal tumor (GIST) xenograft and duration of response after discontinuation of treatment in combination with imatinib.

*Giuseppe Floris*

- Discussion

*Margaret von Mehren, MD*

13 #10021-Adjuvant treatment of high-risk primary uterine leiomyosarcoma with gemcitabine/docetaxel (GT), followed by doxorubicin (D): Results of phase II multicenter trial SARC005.

*Martee Leigh Hensley, MD, MSc*

14 #10022-Long-term follow-up of patients treated with neoadjuvant chemotherapy and radiotherapy for large, extremity soft tissue sarcomas.

*John Thomas Mullen*

15 #10023-A phase II study of neoadjuvant bevacizumab and radiation therapy for resectable soft tissue sarcomas.

*Sam S. Yoon*

16 #10024-Phase I study of sorafenib plus ifosfamide in patients with advanced soft tissue and bone sarcoma: A Spanish Group for Research on Sarcomas (GEIS) study.

*Xavier Garcia del Muro*

17 #10025-Efficacy and toxicity of sorafenib monotherapy in patients with advanced soft tissue sarcoma failing anthracycline-based chemotherapy.

*Alexia Bertuzzi*

18 #10026-A stratified phase II trial investigating sorafenib (SORA) in patients (pts) with metastatic or locally advanced angiosarcoma (AS).

*Nicolas Penel*

- Discussion

*Rashmi Chugh, MD*

19 #10027-Trabectedin (Tr) as single agent for advanced soft tissue sarcomas (STS) failing standard of care: Interim analysis of 1,400 patients (pts) in an expanded access program study.

*Brian Louis Samuels*

20 #10028-Trabectedin (Tr) in the treatment of advanced uterine leiomyosarcomas (U-LMS): Results of a pooled analysis of five single-agent phase II studies using the recommended dose.

*Ian Robert Judson, MD*

21 #10029-Outcomes of patients (pts) with advanced soft-tissue sarcomas (STS) treated in clinical trials (CTs) versus expanded access programs (EAPs): A decade of experience with single-agent trabectedin (Tr).

*George D. Demetri*

22 #10030-Trabectedin (T) in advanced, pretreated synovial sarcomas (SS): A retrospective analysis of 39 patients (pts) from three European institutions.

*Palma Dileo*

23 #10031-Activity of eribulin mesylate (E7389) in patients with soft tissue sarcoma (STS): Phase II studies of the European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group (EORTC 62052).

*Patrick Schoffski, MD, MPH*

24 #10032-Risk of relapse with imatinib (IM) discontinuation at 5 years in advanced GIST patients: Results of the prospective BFR14 randomized phase III study comparing interruption versus continuation of IM at 5 years of treatment: A French Sarcoma Group study.

*Isabelle Ray-Coquard*

25 #10033-Time to onset of progression after imatinib interruption and outcome of patients with advanced GIST: Results of the BFR14 prospective French Sarcoma Group randomized phase III trial.

*Axel Le Cesne*

- Discussion

*James E. Butrynski, MD*

---

**Session Title:** #69: Management of the Elderly Patient with Cancer

**Session Type:** Education Session

**Date:** Tuesday, June 8

**Location:** S100b

**Time:** 11:30 AM - 12:45 PM

- Under representation of the elderly in clinical trials and implications for comparative effectiveness research

*Cary P. Gross, MD*

- Assessing the elderly for therapy

*Arti Hurria, MD*

- Generalizability of clinical trials to the elderly

*Elizabeth B. Lamont, MD, MS*

**Session Title:** #129: Hepatocellular Carcinoma: Is This Patient a Transplant, Resection, or Chemoembolization Candidate?

**Session Type:** Clinical Problems in Oncology Session

**Date:** Tuesday, June 8

**Location:** E451a

**Time:** 11:30 AM - 12:45 PM

- The role of liver transplantation in management of hepatocellular cancer.

*Lynt Johnson*

- The role of intrahepatic interventions in HCC.

*Riad Salem, MD, MBA*

- The role of hepatic resection in management of HCC patients.

*Timothy Pawlik, MD, MPH*

**Session Title:** #252: Lung Cancer - Local-Regional and Adjuvant Therapy

**Session Type:** Poster Discussion Session

**Date:** Tuesday, June 8

**Location:** E354b

**Time:** 12:00 PM - 1:00 PM

- Lung Cancer - Local-Regional and Adjuvant Therapy

*Joseph Kamel Salama, MD*

- Lung Cancer - Local-Regional and Adjuvant Therapy

*Corey J. Langer, MD*

1 #7008-Impact of *KRAS* mutations on adjuvant carboplatin/paclitaxel in surgically resected stage IB NSCLC: CALGB 9633.

*Marzia Capelletti*

2 #7009-Initial results of LC-MAP: An institutional program to routinely profile tumor specimens for the presence of mutations in targetable pathways in all patients with lung adenocarcinoma.

*Mark G. Kris*

3 #7010-Association of genetic variations in DNA-methyltransferases, histone-methyltransferases, and methylated DNA-binding proteins with recurrence and survival in early-stage non-small cell lung cancer treated with surgery alone or surgery and chemotherapy.

*Klaus Wolfgang Wagner*

4 #7011-Impact of *EGFR* and *KRAS* mutations on survival in 1,000 patients with resected lung adenocarcinoma

6 #7013-KRAS and EGFR mutations in the molecular epidemiology of NSCLC: Interim analysis of S0424.

*Philip C. Mack*

- Discussion: Biomarkers in Early Stage NSCLC: Has the future arrived?

*John V Heymach, MD, PhD*

7 #7014-Treatment of the elderly when cure is the goal: The influence of age on treatment selection and efficacy for stage III non-small cell lung cancer (NSCLC).

*Linda E. Coate*

8 #7015-A multinational pooled analysis of 434 cases of stage I non-small cell lung cancer (NSCLC) treated with volumetrically image-guided (VIGRT) stereotactic lung radiotherapy (SBRT): Results from the Elekta Collaborative Lung Research Group.

*Inga S. Grills*

9 #7016-Thoracic radiation therapy in locally advanced NSCLC patients (pts) with EGFR mutations.

*Raymond H. Mak*

- Discussion: New Directions for Radiotherapy in NSCLC

*Jeffrey Bogart, MD*

10 #7017-Utilization of adjuvant therapy among completely resected non-small cell lung cancer (NSCLC) patients in the National Comprehensive Cancer Network (NCCN) outcomes database project.

*Carrie Zornosa, MS*

11 #7018-Adoption of adjuvant chemotherapy for non-small cell lung cancer: A population-based outcomes study.

*Christopher M. Booth, MD*

12 #7019-A phase III adjuvant vinorelbine plus cisplatin (NP) versus NP plus endostar (NPE) in patients (pts) with completely resected stage IB-IIIA non-small cell lung cancer (NSCLC): An interim preliminary result.

*He Jie*

13 #7020-IFCT-GFPC-0701 MAPS trial, a multicenter randomized phase II/III trial of pemetrexed-cisplatin with or without bevacizumab in patients with malignant pleural mesothelioma.

*Gerard Zalcman*

- Discussion: Surgical Perspective on Systemic Therapy for NSCLC and Mesothelioma

*William Roy Smythe, MD*

14 #7021-Validation of the lung cancer staging system revisions using a large prospective clinical trial database (ACOSOG Z0030).

*Juan J. Fibla*

15 #7022-The impact of stage migration on survival after resection in the UICC 7 TNM classification of lung cancer.

*Jan P. Van Meerbeeck*

16 #7023-Prognostic significance of the number of tumor (+) N2 nodes in N2 stage IIIA non-small cell lung cancer after curative resection.

*Changhoon Yoo*

17 #7024-RTOG 0229: A phase II trial of neoadjuvant therapy with concurrent chemotherapy and high-dose radiotherapy (XRT) followed by resection and consolidative therapy for LA-NSCLC.

*Mohan Suntharalingam, MD*

18 #7025-Seven-year follow-up of preoperative chemoradiotherapy in superior sulcus tumor: Report of a Japan Clinical Oncology Group Trial (JCOG9806).

*Masahiro Tsuboi*

19 #7026-Treatment for superior sulcus tumors (SST): Effect of surgery first followed by adjunct concurrent chemoradiotherapy on survival of patients with marginally resectable SST.

*Ritsuko Komaki*

- Discussion: Alternative Approaches to Advanced Resectable NSCLC

*Jessica S. Donington, MD*